New England Regional Coordinating Center for the NINDS Stroke Trials Network

我们建议继续设立新英格兰区域协调中心，这是一个综合小组， 波士顿和马萨诸塞州西部的医院和EMS机构将作为最佳招募地点， NINDS中风试验网络的活跃贡献者。我们的小组包括许多主要的成人学术 大波士顿地区的中风中心，以及我们的30多家新英格兰医院远程中风转诊网络将 进一步扩大我们的招募范围所有的核心医院都有成功的记录， 临床试验的管理和实施。特别是，所有医院都有一个既定的研究 基础设施，在卒中神经病学方面进行持续的临床研究， 学科首席研究员Lee H. Schwamm，MD和合作研究者带来了一套互补的 管理成功的转化临床研究项目的技能，指导委员会成员， 以及在各自领域的国家领导地位。我们的团队包括血管领域经验丰富的临床研究人员， 神经病学、急诊医学、神经血管内、神经外科、神经重症监护、神经影像学、卒中 康复，以及成人和儿童的临床前基础和转化性卒中研究。优势 NERCC团队的优势包括：1）多名研究人员之间密切的个人和专业联系; 2） 来自主要大都市地区不同医院环境的患者人群; 3）研究中心的优秀团队 具有多中心科学成就、创新和受试者招募跟踪记录的研究者 试验; 4）强大的现有NINDS资助的研究和临床试验管理基础设施; 5）现有的临床 研究项目，例如，神经病学临床研究所，NIH临床和转化科学奖 在波士顿大学和整个哈佛计划;在SIREN和NeuroNEXT临床协调的网站 中心总的来说，NERCC团队在第一个项目中表现出了出色的承诺和表现。 StrokeNet循环，并有资源，愿景和热情，继续开发新的翻译 科学和成功地执行NINDS StrokeNet第1、2和3期试验。

We propose to continue the New England Regional Coordinating Center (NERCC), an integrated team of hospitals and EMS agencies in Boston and Western Massachusetts that will serve as a top-enrolling site and vibrant contributor to the NINDS Stroke Trials Network. Our group includes many of the major adult academic stroke centers in the Greater Boston area, and our 30+ hospital New England TeleStroke referral network will extend our potential recruitment even further. All core hospitals have a proven track record of successful management and performance of clinical trials. In particular, all hospitals have an established research infrastructure that performs ongoing clinical research in stroke neurology with strong collaborations across disciplines. Principal investigator Lee H. Schwamm, MD, and Co-Investigators bring a complementary set of skills in managing successful translational clinical research programs, membership on Steering Committees, and positions of national leadership in their fields. Our team includes seasoned clinical investigators in vascular neurology, emergency medicine, neuroendovascular, neurosurgery, neurointensive care, neuroimaging, stroke rehabilitation, and preclinical basic and translational stroke investigation in both adults and children. Strengths of the NERCC team include 1) close personal and professional ties between multiple investigators; 2) large patient population from diverse hospital settings in a major metropolitan area; 3) talented teams of site investigators with track records of scientific achievement, innovation, and subject recruitment in multicenter trials; 4) robust existing NINDS-funded research and clinical trial management infrastructure; 5) existing clinical research programs, e.g., Neurology Clinical Research Institute, NIH Clinical and Translational Science Award programs at Boston University and across Harvard; Sites in the SIREN and NeuroNEXT Clinical Coordinating Center. Overall, the NERCC Team has demonstrated outstanding commitment and performance in the first StrokeNet cycle, and has the resources, vision, and enthusiasm to continue to develop new translational science and successfully execute the NINDS StrokeNet Phase 1,2 and 3 trials.